Clinical data | |
---|---|
Trade names | Matulane, Natulan, Indicarb, others |
AHFS/Drugs.com | Monograph |
MedlinePlus | a682094 |
Pregnancy category |
|
Routes of administration | By mouth (gel capsule), intravenous |
ATC code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Metabolism | liver, kidney |
Elimination half-life | 10 minutes |
Excretion | kidney |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.010.531 |
Chemical and physical data | |
Formula | C12H19N3O |
Molar mass | 221.304 g·mol−1 |
3D model (JSmol) | |
| |
| |
(what is this?) (verify) |
Procarbazine is a chemotherapy medication used for the treatment of Hodgkin's lymphoma and brain cancers.[1] For Hodgkin's it is often used together with chlormethine, vincristine, and prednisone while for brain cancers such as glioblastoma multiforme it is used with lomustine and vincristine.[1] It is typically taken by mouth.[1]
Common side effect include low blood cell counts and vomiting.[1] Other side effects include tiredness and depression.[2][3] It is not recommended in people with severe liver or kidney problems.[4] Use in pregnancy is known to harm the baby.[1] Procarbazine is in the alkylating agents family of medication.[1] How it works is not clearly known.[1]
Procarbazine was approved for medical use in the United States in 1969.[1] It is on the World Health Organization's List of Essential Medicines.[5][6] In the United Kingdom a month of treatment cost the National Health Service 450 to 750 pounds.[4]